Quick Facts About Vacta

• Primary Use: Supports the body's defenses against hepatitis A virus infection.
• Recommended For: Individuals 12 months of age and older.
• Therapeutic Domain: Active immunization to help prevent disease.

---

Vacta is a vaccine approved for use in persons 12 months of age and older. Its primary function is to support the body's ability to develop immunity to the disease caused by the hepatitis A virus (HAV). It is indicated for active immunization for the prevention of disease caused by the virus.

Healthcare professionals may recommend Vacta for persons who may be at an elevated risk of infection, which can include travelers to certain areas or individuals in specific occupational or community settings. The vaccine's purpose is to help safeguard against HAV infection, which may provide protection from the liver disease associated with the virus. The goal of vaccination is to help ensure a positive public health response by supporting protection against the spread of the virus.

For official guidance on the appropriate use and indications for this vaccine, consult the approved labeling.

Eligibility for Vacta

Official regulatory information defines the specific population groups permitted, restricted, or prohibited from using Vacta (Hepatitis A Vaccine, Inactivated).

Category	Eligibility Status (Regulatory)
Approved Age Groups	Indicated for persons 12 months of age and older.
Contraindicated Groups	Must not be administered to individuals with a history of immediate, severe allergic reactions (anaphylaxis) to a previous dose of any Hepatitis A vaccine or to any component of Vacta, including neomycin.
Infants	Use in infants below 12 months of age is not established, as sufficient data on safety and effectiveness is unavailable.
Acute Illness	Vaccination should be deferred in persons with a moderate or severe acute illness, with or without fever, until recovery.
Immune Status	Immunocompromised individuals may have a diminished immune response and may not achieve full protection against the Hepatitis A virus.
Pregnancy and Lactation	No adequate and well-controlled studies exist for use in pregnant women. Use is considered only when the potential benefit outweighs the risk, particularly in high-risk exposure situations. Caution is advised during lactation as it is unknown if the vaccine is excreted in human milk.

---

The eligibility profile is strictly defined by an Age Minimum and Absolute Contraindications. Populations with acute illness or compromised immune function face Conditional Restrictions where the vaccine may be given cautiously or postponed, as stated in official labeling.

Interactions with other medicines and products

Impact of Immunosuppressive Therapy

Vacta (Hepatitis A Vaccine, Inactivated) is subject to a documented pharmacodynamic interaction with immunosuppressive treatments. Official regulatory documents indicate that the expected immune response, including the rate of seroconversion, may be diminished in individuals who are receiving immunosuppressive therapy. This category includes but is not limited to radiation therapy, corticosteroids used at greater than physiologic doses, alkylating agents, and antimetabolites.

Concomitant Use with Other Vaccines

Concomitant administration with certain other vaccines has been evaluated and is permitted, provided that separate injection sites and separate syringes are used for each injectable product. Regulatory documents specifically note that Vacta may be co-administered with immune globulin, also requiring separate sites and syringes. Data confirm that the immune response to Vacta is not generally affected when given simultaneously with vaccines such as measles, mumps, rubella, varicella, and pneumococcal 7-valent conjugate vaccines.

Interaction Constraints

The essential interaction constraint is the potential for reduced efficacy when the immune system is suppressed by other medicines. The official information structures its constraints around two main areas: preventing blunted therapeutic effect in immunocompromised persons, and establishing logistical rules for simultaneous administration of multiple injectable products to ensure their independent delivery.

How Vacta Works

Vacta is a selective, high-affinity inhibitor that targets the farnesyl pyrophosphate synthase (FPPS) enzyme within the mevalonate pathway. Following cellular uptake, Vacta accumulates preferentially in osteoclasts due to their high metabolic activity and FPPS expression. Once internalized, the drug binds to the active site of FPPS, competitively blocking the conversion of farnesyl pyrophosphate to geranylgeranyl pyrophosphate.

This inhibition prevents the prenylation of small GTPases, such as Rac and Rho, which are critical for cytoskeletal rearrangement, necessary for the osteoclast's ruffled border formation and adhesion. Consequently, Vacta disrupts the osteoclast's functional integrity, leading to cellular inactivation and subsequent programmed cell death. The resulting decrease in osteoclast number and activity shifts the bone remodeling balance by reducing the rate of bone matrix demineralization.

Official Administration Guidelines for VAQTA

VAQTA (Hepatitis A Vaccine, Inactivated) is administered via a two-dose schedule, with specific instructions for dosing volume and route based on the recipient's age.

Dosing Schedule and Volume
Children/Adolescents (12 months through 18 years): 0.5 mL (25 U)
Adults (19 years and older): 1.0 mL (50 U)

Administration Scope

• Route of Administration: The vaccine is for intramuscular (IM) injection only. The preferred site for administration is the deltoid muscle (upper arm) for adults and older children. For children 12 through 23 months of age, the anterolateral area of the thigh is the preferred site.
• Bleeding Disorders: For individuals with bleeding disorders (e.g., haemophiliacs) who are at risk of hemorrhage from IM injection, the vaccine may be administered subcutaneously (SC).
• Timing and Frequency: The vaccination series consists of one primary dose and one booster dose. The booster dose is administered 6 to 18 months after the primary dose.

Preparation and Procedural Steps

Before use, the suspension should be shaken well to achieve a slightly opaque, white appearance. The product must be visually inspected for particulate matter or discoloration prior to administration. The vaccine must not be mixed with any other vaccine in the same syringe. If concurrent administration of other vaccines or immune globulin is necessary, separate injection sites and separate syringes must be used.

Age-Specific Rules: The two distinct formulations (0.5 mL and 1.0 mL) define the dose and strength that must be selected based on the recipient's age group. Safety and effectiveness have not been established in infants younger than 12 months of age.

Research evidence / Overview of studies for Vacta

Evidence for Preventing Hepatitis A in the General Population

Vacta was studied for active immunization in research exploring outcomes related to Hepatitis A Virus (HAV). These studies typically included healthy children starting from 12 months of age, as well as healthy adolescents and adults, and used Randomized Controlled Trials (RCTs) and long-term observational studies. Researchers examined how the body responds to the vaccine, using research to explore the measurement of anti-HAV antibodies.

Research highlights changes measured during the study period, with short-term trials reporting that many participants demonstrated seroconversion (a laboratory finding of antibody presence) following the vaccine schedule. These findings describe patterns observed in the studies and relate to how patients reported their experience during the trial period. The evidence contributes to the broader understanding of symptom patterns.

The primary outcome measured in many of these early trials was seroconversion (the change in antibody levels), which is a laboratory marker, or surrogate biomarker, rather than the direct, primary prevention of clinical infection. While this marker is observed in some studies, research does not determine whether an individual will respond similarly, as findings describe group patterns, not personal outcomes.

---

Research on Antibody Response and Persistence

This part details the high-level outcomes examined in the clinical research, specifically focusing on the measurement of seroconversion rates and the magnitude of the antibody response, which are monitored markers in studies of vaccine response. Studies monitored these outcomes over defined time intervals.

Studies explored the seroconversion rate (SCR), which is the proportion of people who reach a certain antibody level after vaccination. Data show patterns related to seroconversion in the observed populations. Research also examined the Geometric Mean Concentrations (GMCs), which provide a measurement of the average amount of antibody created, allowing researchers to track the magnitude of the immune response.

Long-Term Studies and Follow-Up Data

Long-term cohort studies were studied for the persistence of these antibody levels over time. These studies were designed to track how long protective antibodies lasted after the primary vaccination series. Findings describe patterns observed in these studies, reporting that anti-HAV antibody persistence was observed in some studies over periods of up to 6 to 10 years in the specific cohorts evaluated.

Long-term outcomes, however, are not fully established. Evidence regarding the persistence of protective antibody levels beyond the 10-year observation period is limited and often relies on specialized calculations or modeling by scientists. Follow-up durations were limited in the initial core trials, meaning data for very long-term outcomes remain insufficient.

---

Evidence in Specific and Immunocompromised Populations

Vacta was evaluated in specific groups, including adults living with HIV infection and patients receiving certain immunosuppressive therapy. These studies used RCTs and observational cohorts to track the immune response in people in studied populations with certain underlying conditions compared to the general population.

Studies focusing on these groups explored the seroconversion rate and the magnitude of the antibody response. Findings varied across studies and specific populations. Studies reported that the proportion of individuals with observed seroconversion varied, and the antibody levels appeared to be lower or less consistent in individuals with certain characteristics, such as lower cell counts, compared to healthy individuals. Research describes patterns indicating that persistence of the antibody response was observed in some studies to be shorter in some of these cohorts.

Research in Children and Adolescents

Research explored the immune response in children and how the response related to that of adolescents and adults, beginning from 12 months of age. Research examined how children's immune systems reacted and how the response related to that of adolescents and adults. Findings relate to how children reported their experience in the studies.

---

Key Limitations and Remaining Research Gaps

Research provides context but not individual predictions, and the evidence highlights what is known and what is still uncertain. The results apply only to the populations studied.

One of the key limitations is that the majority of research uses seroconversion (the laboratory finding) as a marker, rather than focusing solely on the direct prevention of clinical disease. This approach means the evidence for these outcomes is primarily based on a surrogate biomarker.

Furthermore, follow-up durations were limited in the initial trials, meaning there is limited information for long-term outcomes, particularly beyond the 10-year mark described in some observational studies. The evidence quality varies across studies when examining special populations, and data for certain groups, such as some immunocompromised cohorts, remain insufficient or have mixed findings.

Common questions about Vacta (FAQ)

---

Q: What makes Vacta different from other options used for the same purpose?

A: Vacta is described in official product information as a monovalent, inactivated vaccine. This means its components target only the Hepatitis A virus, and the viral material has been chemically killed, ensuring it cannot cause disease. The product also contains an aluminum adjuvant, a component added to help prompt the body's immune response.

---

Q: Are there any known interactions between Vacta and herbal supplements?

A: Official regulatory documents and prescribing information primarily focus on documented interactions with other vaccines and medicines that suppress the immune system. Specific interactions involving herbal supplements or alternative remedies are not generally addressed in the core prescribing information for Vacta.

---

Q: Does Vacta interact with alcohol?

A: Official regulatory documents do not list a specific interaction or constraint regarding the consumption of alcohol with Vacta. Regulatory constraints primarily relate to medicines documented to potentially diminish the expected immune response by suppressing the immune system.

---

Q: What kind of specialist typically prescribes Vacta?

A: Vacta is a prescription-only vaccine that is administered by a licensed healthcare professional. This often includes pediatricians (for children), primary care physicians, or specialists who work in areas such as travel health or public health settings.

---

Q: How common are the listed side effects of Vacta?

A: Official safety documents categorize the frequency of reported side effects based on how often they occurred in clinical trials. Side effects are described using terms like 'Very Common' (affecting 1 in 10 or more people), 'Common' (affecting 1 in 100 to less than 1 in 10 people), and 'Less Common' (affecting less than 1 in 100 people).

---

Q: Does Vacta need to be taken consistently at the same time each day?

A: Vacta is an intramuscular vaccine given in a two-dose series separated by several months, not a daily oral medication. Official instructions specify the minimum interval and recommended window between the two doses, but they do not require the vaccine to be administered at a consistent time of day.

---

Q: Are there any major research findings about Vacta that I should know about?

A: Clinical trials examined Vacta's ability to help the body create protective anti-Hepatitis A virus antibodies. Research findings describe that many participants demonstrated seroconversion (the laboratory finding of antibodies present) following the vaccination schedule.

---

Q: Can over-the-counter pain relievers be taken with Vacta?

A: The official product labeling does not specify a contraindication or interaction with common over-the-counter (OTC) pain relievers. The main focus of documented interactions is on immunosuppressive therapies.

---

Q: How quickly does Vacta typically start working?

A: Official instructions indicate that the primary dose of Vacta should be given at least two weeks before the expected exposure to the Hepatitis A virus. This two-week period is indicated in relation to the expected exposure, reflecting the necessary time frame used in regulatory guidance.

---

Q: What is the typical timeframe or duration of Vacta's effects?

A: Clinical studies have examined the persistence of anti-Hepatitis A virus antibodies. Research findings describe antibody presence observed in specific study cohorts for periods of up to 6 to 10 years following the vaccination series.

---

Q: Does Vacta cause tiredness or difficulty sleeping?

A: Reported side effects include general fatigue and somnolence (drowsiness), which are listed as common or less common effects. In addition, difficulty sleeping, known as insomnia, has also been reported as an uncommon side effect in official safety documentation.

---

Q: Can Vacta be taken by people with kidney problems?

A: Official labeling does not list kidney problems as a specific contraindication. However, regulatory information notes that conditions such as being immunocompromised may be associated with a diminished immune response to the vaccine.

---

Q: Is it okay to drink coffee or caffeine while on Vacta?

A: Official regulatory documents do not list any specific interaction or constraint regarding the consumption of coffee or caffeine while receiving Vacta.

---

Q: Are there special dietary instructions when using Vacta?

A: Official administration and usage instructions for Vacta do not include any special dietary requirements, restrictions, or constraints.

---

Q: What happens if I miss a scheduled amount of Vacta?

A: Vacta is administered as a two-dose series (primary and booster). Regulatory patient information describes that if the second dose is missed or administered outside the recommended timing, guidance from a healthcare professional is typically needed for the proper continuation of the schedule.

---

Q: Does Vacta have withdrawal effects if stopped suddenly?

A: Vacta is a vaccine given in a two-dose series, not a long-term daily medication. Withdrawal effects are not described in the official safety information.

---

Q: Is Vacta compatible with breastfeeding?

A: Official documents state that it is unknown if Vacta is excreted in human milk. Caution is advised when administering the vaccine to a nursing woman, and its use is based on evaluating potential benefit against risk.

---

Q: Does taking Vacta affect laboratory blood tests?

A: Vacta's clinical trials involved measuring the presence of anti-Hepatitis A antibodies through laboratory blood tests. However, there are no warnings in regulatory documents indicating that the vaccine interferes with standard, general diagnostic lab test results.

---

Q: What is the typical purpose of Vacta for chronic conditions?

A: Vacta is indicated solely for the prevention (prophylaxis) of disease caused by the Hepatitis A virus in persons 12 months of age and older.

---

Q: Does Vacta have a generic version available?

A: Vacta is the brand name for this specific Hepatitis A vaccine. While other brands of Hepatitis A vaccine exist, Vacta itself does not have a generic equivalent listed in official documentation.

---

Q: Is Vacta a controlled substance?

A: Vacta is classified as a vaccine and is not listed as a controlled substance under U.S. federal regulation.

---

Q: Can Vacta affect my mood or mental clarity?

A: The most frequently reported central nervous system side effects are headache and dizziness, with somnolence (drowsiness) also reported. In children, irritability is a reported side effect. Changes in mood or mental clarity beyond these effects are not specifically listed in the official documents.

---

Q: Are there any specific activities or machinery I should avoid while using Vacta?

A: Official product information notes that, due to reported side effects such as headache, dizziness, and drowsiness, caution is typically advised when performing tasks that require mental alertness, such as driving or operating machinery.

---

Q: Is it possible to be allergic to Vacta?

A: Yes, Vacta is contraindicated (must not be used) in individuals with a history of an immediate or severe allergic reaction to a previous dose of any Hepatitis A vaccine. It is also contraindicated for those allergic to any component of the vaccine, including neomycin.

---

Q: Are there any known long-term effects of taking Vacta?

A: The long-term safety profile is monitored through clinical trials and post-marketing surveillance to document adverse reactions. Official documents note that the persistence of protective antibody levels beyond the 10-year observation period is limited.

---

Q: Can Vacta be taken during pregnancy?

A: Official documents state that no adequate and well-controlled studies exist for Vacta use in pregnant women. Use is generally based on evaluating potential benefit against potential risk, particularly in high-risk exposure situations.

How to Store and Dispose of Vacta

Official regulatory documents define the required storage and disposal conditions for Vacta (Hepatitis A Vaccine, Inactivated) to maintain its potency.

Storage Requirements

Condition	Requirement
Temperature	Store refrigerated at 2 C to 8 C (36 F to 46 F).
Freezing	Do not freeze; freezing destroys the vaccine's potency, and the product must be discarded if frozen.
Protection	Keep in the original package to protect from light.
Safety	Store the vaccine out of the sight and reach of children.

Handling and Disposal

Before use, the vaccine must be shaken well to achieve a homogeneous suspension. Any unused medicinal product or waste material must be disposed of in accordance with local requirements for pharmaceutical waste. Environmental precautions require avoiding contact of spilled material and runoff with soil and surface waterways.